×
About 10 results

B Cell Test Predicts Alemtuzumab Autoimmunity in MS
https://www.medscape.com/viewarticle/937434

Sep 14th, 2020 - A common adverse effect of the multiple sclerosis (MS) treatment alemtuzumab (Lemtrada) may be predicted by pre-treatment levels of certain types of B cells, a new study suggests. Dr Paulette Walo "Alemtuzumab has proven to be an effective treatment for patients with highly active remitting relapsing MS, but adverse events may limit the use of this drug, particularly autoimmune adverse events, ...

Are You Honest When Patients Ask, 'What Would You Do?'
https://www.staging.medscape.com/viewarticle/929664

May 6th, 2020 - This transcript has been edited for clarity. Hello. I'm David Kerr, professor of cancer medicine from the University of Oxford in England. I'd like to share with you a uniquely interesting consultation I had at clinic last week. It shouldn't be a surprise that, working in a large hospital in a university town like Oxford, we get a lot of academics as patients. They fall into two broad groups, a...

Are You Honest When Patients Ask, 'What Would You Do?'
https://www.medscape.com/viewarticle/929664

May 6th, 2020 - This transcript has been edited for clarity. Hello. I'm David Kerr, professor of cancer medicine from the University of Oxford in England. I'd like to share with you a uniquely interesting consultation I had at clinic last week. It shouldn't be a surprise that, working in a large hospital in a university town like Oxford, we get a lot of academics as patients. They fall into two broad groups, a...

SGLT2, Fournier Gangrene Link Is 'Compelling'--What to Do?
https://www.medscape.com/viewarticle/912369

May 7th, 2019 - Welcome to Impact Factor, your weekly commentary on a breaking medical study. I'm Perry Wilson. A new class of medications, the SGLT2 inhibitors, has been killing it lately, with study after study in the New England Journal of Medicine documenting their benefits in patients with diabetes. Many of us feel that these drugs will become a central part of diabetes therapy in the near future. The twi...

Kratom: What We Know
https://www.medscape.com/viewarticle/874301

Jan 22nd, 2017 - This is Dr Charles Argoff, professor of neurology at Albany Medical College in Albany, New York, and director of the Comprehensive Pain Center at Albany Medical Center. The US Drug Enforcement Administration (DEA) recently declared that it will hold off on a previously announced ban of the herbal drug kratom, as there was a need for additional input regarding this decision from the public and t...

Hydrocortisone Helps Reduce Serious Neuropsychologic Adverse Events for Pediatric Acute Lymphocytic Leukemia Patients Receiving Dexamethasone
https://www.ashclinicalnews.org/news/hydrocortisone-helps-reduce-serious-neuropsychologic-adverse-events-for-pediatric-acute-lymphocytic-leukemia-patients-receiving-dexamethasone/

Nov 1st, 2016

SGLT2, Fournier Gangrene Link Is 'Compelling'--What to Do?
https://emedicine.medscape.com/viewarticle/912369

Welcome to Impact Factor, your weekly commentary on a breaking medical study. I'm Perry Wilson. A new class of medications, the SGLT2 inhibitors, has been killing it lately, with study after study in the New England Journal of Medicine documenting their benefits in patients with diabetes. Many of us feel that these drugs will become a central part of diabetes therapy in the near future. The twi...

Are You Honest When Patients Ask, 'What Would You Do?'
https://emedicine.medscape.com/viewarticle/929664

This transcript has been edited for clarity. Hello. I'm David Kerr, professor of cancer medicine from the University of Oxford in England. I'd like to share with you a uniquely interesting consultation I had at clinic last week. It shouldn't be a surprise that, working in a large hospital in a university town like Oxford, we get a lot of academics as patients. They fall into two broad groups, a...

Mefloquine-Associated Dizziness, Diplopia, and Central Serous Chorioretinopathy
https://www.medscape.com/viewarticle/871366

Abstract and Introduction Abstract Background: Many acute and chronic neurological sequelae from the quinoline derivative antimalarial drug mefloquine, including dizziness and effects on the visual system such as diplopia and blurred vision, may be attributable to focal central nervous system toxicity. Maculopathy has also been reported with use of mefloquine, although the mechanism of this eff...

Mefloquine-Associated Dizziness, Diplopia, and Central Serous Chorioretinopathy
https://www.medscape.com/viewarticle/871366_2

Background Mefloquine is a quinoline derivative antimalarial drug structurally related to quinine that has been previously widely used in the treatment and prophylaxis of malaria. Recently its popularity has declined as awareness has grown of the drug's focal central nervous system (CNS) toxicity, which is associated with a wide range of acute and chronic neurological sequelae including vertigo...